MA37951B2 - Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium - Google Patents
Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésiumInfo
- Publication number
- MA37951B2 MA37951B2 MA37951A MA37951A MA37951B2 MA 37951 B2 MA37951 B2 MA 37951B2 MA 37951 A MA37951 A MA 37951A MA 37951 A MA37951 A MA 37951A MA 37951 B2 MA37951 B2 MA 37951B2
- Authority
- MA
- Morocco
- Prior art keywords
- irbesartane
- atorvastatin
- magnesium carbonate
- tablet formulation
- bilayer tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une formulation de comprimé composite bicouche comprenant (a) une première couche comportant de l'irbesartane ou son sel pharmaceutiquement acceptable, et (b) une seconde couche comportant de l'atorvastatine ou son sel pharmaceutiquement acceptable et du carbonate de magnésium (m
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120096477A KR20140028971A (ko) | 2012-08-31 | 2012-08-31 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
PCT/KR2013/007838 WO2014035188A1 (fr) | 2012-08-31 | 2013-08-30 | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37951A1 MA37951A1 (fr) | 2018-06-29 |
MA37951B2 true MA37951B2 (fr) | 2019-12-31 |
Family
ID=50183917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37951A MA37951B2 (fr) | 2012-08-31 | 2013-08-30 | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium |
Country Status (31)
Country | Link |
---|---|
US (1) | US20150209290A1 (fr) |
EP (1) | EP2890368A4 (fr) |
JP (1) | JP6363079B2 (fr) |
KR (1) | KR20140028971A (fr) |
CN (1) | CN104602677A (fr) |
AR (1) | AR092386A1 (fr) |
AU (1) | AU2013309686B2 (fr) |
BR (1) | BR112015004471A8 (fr) |
CA (1) | CA2882735A1 (fr) |
CL (1) | CL2015000402A1 (fr) |
CR (1) | CR20150115A (fr) |
DO (1) | DOP2015000040A (fr) |
EA (1) | EA030306B1 (fr) |
EC (1) | ECSP15010600A (fr) |
GT (1) | GT201500043A (fr) |
IL (1) | IL237424A0 (fr) |
IN (1) | IN2015DN01463A (fr) |
MA (1) | MA37951B2 (fr) |
MX (1) | MX354800B (fr) |
MY (1) | MY175897A (fr) |
NI (1) | NI201500027A (fr) |
NZ (1) | NZ706472A (fr) |
PE (1) | PE20150935A1 (fr) |
PH (1) | PH12015500394A1 (fr) |
RU (1) | RU2015111546A (fr) |
SG (1) | SG11201500584YA (fr) |
TW (1) | TWI651101B (fr) |
UA (1) | UA115995C2 (fr) |
UY (1) | UY35001A (fr) |
WO (1) | WO2014035188A1 (fr) |
ZA (1) | ZA201502156B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6981088B2 (ja) * | 2017-01-27 | 2021-12-15 | ニプロ株式会社 | 経口固形製剤 |
CR20190577A (es) * | 2017-07-17 | 2020-01-29 | Lilly Co Eli | Composiciones farmacéuticas |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
PE20030324A1 (es) | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
KR20090114325A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 약제학적 제제 |
JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
-
2012
- 2012-08-31 KR KR1020120096477A patent/KR20140028971A/ko active Search and Examination
-
2013
- 2013-08-29 AR ARP130103083A patent/AR092386A1/es unknown
- 2013-08-30 TW TW102131243A patent/TWI651101B/zh not_active IP Right Cessation
- 2013-08-30 JP JP2015529683A patent/JP6363079B2/ja not_active Expired - Fee Related
- 2013-08-30 IN IN1463DEN2015 patent/IN2015DN01463A/en unknown
- 2013-08-30 NZ NZ706472A patent/NZ706472A/en not_active IP Right Cessation
- 2013-08-30 EP EP13833700.1A patent/EP2890368A4/fr not_active Withdrawn
- 2013-08-30 UY UY0001035001A patent/UY35001A/es not_active Application Discontinuation
- 2013-08-30 AU AU2013309686A patent/AU2013309686B2/en not_active Ceased
- 2013-08-30 MX MX2015002526A patent/MX354800B/es active IP Right Grant
- 2013-08-30 MY MYPI2015700489A patent/MY175897A/en unknown
- 2013-08-30 CA CA2882735A patent/CA2882735A1/fr not_active Abandoned
- 2013-08-30 US US14/421,467 patent/US20150209290A1/en not_active Abandoned
- 2013-08-30 CN CN201380045377.2A patent/CN104602677A/zh active Pending
- 2013-08-30 MA MA37951A patent/MA37951B2/fr unknown
- 2013-08-30 WO PCT/KR2013/007838 patent/WO2014035188A1/fr active Application Filing
- 2013-08-30 PE PE2015000220A patent/PE20150935A1/es not_active Application Discontinuation
- 2013-08-30 EA EA201590469A patent/EA030306B1/ru not_active IP Right Cessation
- 2013-08-30 SG SG11201500584YA patent/SG11201500584YA/en unknown
- 2013-08-30 UA UAA201502939A patent/UA115995C2/uk unknown
- 2013-08-30 BR BR112015004471A patent/BR112015004471A8/pt not_active IP Right Cessation
- 2013-08-30 RU RU2015111546A patent/RU2015111546A/ru unknown
-
2015
- 2015-02-19 CL CL2015000402A patent/CL2015000402A1/es unknown
- 2015-02-24 PH PH12015500394A patent/PH12015500394A1/en unknown
- 2015-02-25 IL IL237424A patent/IL237424A0/en unknown
- 2015-02-26 DO DO2015000040A patent/DOP2015000040A/es unknown
- 2015-02-26 GT GT201500043A patent/GT201500043A/es unknown
- 2015-02-27 NI NI201500027A patent/NI201500027A/es unknown
- 2015-03-05 CR CR20150115A patent/CR20150115A/es unknown
- 2015-03-20 EC ECIEPI201510600A patent/ECSP15010600A/es unknown
- 2015-03-30 ZA ZA2015/02156A patent/ZA201502156B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291613A (en) | Anticoagulant monoclonal antibodies (anti–factor xii/fxiia), method for their preparation, pharmaceutical compound containing them and medical uses | |
BR112012024139A2 (pt) | formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide. | |
WO2012177443A3 (fr) | Co-agonistes du récepteur du glucagon et du récepteur du gpl-1 | |
CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
NL1031503A1 (nl) | Stereoscopisch beeldscherm voor omschakelen tussen 2D/3D beelden. | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
DK2442790T3 (da) | Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser | |
EP2610226A4 (fr) | Film intermédiaire pour verre feuilleté, et verre feuilleté | |
FR3003747B1 (fr) | Systeme pour abouter deux vaisseaux sanguins. | |
EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
MX2016003754A (es) | Una composicion farmaceutica estable que contiene amlodipina y valsartan. | |
EA201491517A1 (ru) | N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения | |
WO2015073710A3 (fr) | Détection du risque de maladie cardiovasculaire athéroscléreuse et du risque d'infarctus du myocarde | |
IL232061A (en) | The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use | |
IT1397313B1 (it) | Unita' di taglio per macchina o pressa di termoforatura e macchina di termoforatura dotata di tale unita' di taglio. | |
MA37951B2 (fr) | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium | |
MA34709B1 (fr) | Compositions pharmaceutiques | |
WO2011097527A3 (fr) | Immunoprotection de fractions thérapeutiques avec des régions fc améliorées | |
WO2011091410A8 (fr) | Antagonistes de trpv4 | |
WO2011136489A3 (fr) | Capteur d'image pour capsule endoscopique permettant un fonctionnement à deux modes | |
EA201190282A1 (ru) | Фармацевтическая композиция, содержащая тамсулозин | |
WO2019059857A3 (fr) | Dispositif pour combiner plusieurs médicaments | |
WO2015044434A3 (fr) | Fluoro-9-méthyl-β-carboline | |
EA201301355A1 (ru) | Композиция и таблетка, содержащая ралтегравир | |
WO2012016646A9 (fr) | Comprimés de quétiapine |